Skip to content
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · LARGE CAP

TransMedics Group, Inc. TMDX

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$605.5M
▲ 37.1% YoY
$190.3M
▲ 436.6% YoY
$133.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

TransMedics Group, Inc. developed the OCS, a portable, multi-organ, warm perfusion platform, and has developed three OCS products, one for each of lung, heart and liver transplantation. Each OCS product consists of three primary components customized for each organ: an OCS Console, an OCS Perfusion Set and OCS Solutions. As of December 31, 2025, it employed 898 people globally, most of whom were full-time and located in the United States. It also operates its NOP, a turnkey solution that provides outsourced organ procurement, OCS perfusion management and transplant logistics services, including aviation transportation, ground transportation and other coordination activity, to transplant programs in the United States. It designs and assembles its OCS Consoles and disposable OCS Perfusion Sets at its facility in Andover, Massachusetts. TransMedics Group, Inc. was incorporated in the Commonwealth of Massachusetts in October 2018 to facilitate its initial public offering, and its wholly owned operating subsidiary, TransMedics, Inc., was incorporated in the State of Delaware in August 1998.

Written from the business description in TransMedics Group, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.

Growth

USD 605.5M
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2025 · Revenue 605.5 · Net income 190.3
250.0M500.0M
2018202120242025
Compound annual growth
+86.4%
+88.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +88.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

31 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 17.9% · Net 31.4%
10%20%30%-50%-100%-150%
201820212025
ROE
FY2025 · ROE 54.2%
20%40%-20%-40%
201820212025
Three returns, three denominators.

Each USD of equity produced 54 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 133.6
50M100M-100M-200M
201820212025

Total assetsUSD 1.1B
EquityUSD 473.1M
CashUSD 488.9M
Gross debtUSD 10.0M
Net debtUSD -478.9M
Current ratio7.14×

The company holds more cash than debt.

The 8-year record

8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
TMDX, 8-year financial record
Metric 20252024202320222021202020192018
Revenue $B0.60.40.20.10.00.00.00.0
Operating income $B0.10.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B0.10.1−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B−0.10.0−0.00.0◌0.00.00.0
Net income $B0.20.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.1−0.1−0.2−0.1−0.0−0.0−0.0−0.0
EPS, diluted $4.871.01−0.77−1.23−1.60−1.16−2.36−17.48
Dividend / sh $0.000.000.000.000.000.000.00◌
Payout % — not applicable: no dividend————————
ROE %54.219.4−15.4−28.4−51.5−36.3——
Shares out B0.030.030.030.030.030.03◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 41 reconciliationsAUDITED

Reconciled in 8 of the 8 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 11 checks were skipped: EPS is not tagged before 2018. 11 checks were skipped: revenue is not tagged before 2018.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onNASDAQ
Incorporated inMassachusetts
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image